Microcurrent therapy (MCT) is an emerging field within medicine. Our goal was to explore MCT effect on autism spectrum disorder (ASD) patients using a pilot study. 21 pediatric patients and 1 adult with ASD received an average of 32 MCT sessions using a standardized protocol. The Autism Treatment Evaluation Checklist (ATEC) pre- and post-MCT assessed symptom severity. We compared pre- and post-MCT ATEC scores; compared MCT ATEC scored with aged-matched historical controls, and determined dose response. There were no serious side effects, and the therapy was well tolerated. 22 patients completed 32 sessions on average. In paired t-testing, MCT produced a statistically significant average decrease of 28.6 (42.8%) on ATEC (p = 0.007; 95% CI = 8.3-48.9). In unpaired t-testing comparing MCT with age-matched historical controls, the treatment group average improvement was 26.4 (42.6%), compared to aged-matched controls of 7.9 (13.2%) (p=0.0001; 95% CI 19.9 - 47.5). Linear regression showed a strong direct relationship between the number of microcurrent sessions and magnitude of improvement R = 0.693; F = 18.5; P = 0.0003; CI: 95%. Initial evidence showed MCT can reduce ASD symptoms.